BI/Lilly Bring Third Entrant To SGLT2 Market With Jardiance Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
The type 2 diabetes space gets more crowded as FDA hands out another approval for an SGLT-2 inhibitor after an earlier rejection in March due to manufacturing issues.